Petra Kaufmann, M.D.
Chief Medical Officer
Petra most recently served as senior vice president and head of clinical development, analytics, and translational medicine at Novartis Gene Therapies, where she played a key role in the global approvals of the gene therapy Zolgensma® and in advancing Investigational New Drug (IND) submissions. Petra’s expertise in translational medicine and clinical development in neuroscience, rare disease, and gene therapy comes from many years of clinical research and development positions in academia and at the National Institutes of Health (NIH), where she held leadership roles of increasing responsibility, most recently as director of the Office of Rare Diseases Research. Petra earned an M.S. in biostatistics at Columbia University, where she also trained in neurology and served as a tenured faculty member, advancing research, and caring for patients. She received an M.D. at the University of Bonn.